Abstract
Prospective reports suggest metastasis-directed therapy (MDT) in oligometastatic castration-sensitive prostate cancer (omCSPC) is associated with improved treatment outcomes. When the addition of androgen-deprivation therapy (ADT) to MDT for omCSPC is needed is unclear. Here we assess the ability of an androgen receptor activity (AR-A) signature to provide prognostic information for omCSPC patients treated with MDT without and with ADT.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
